Although rosiglitazone had a sparing effect on beta cell function and decrease FFA, triglycerides and PAI-1 levels, it was recently excluded from the marked due to an increase in cardiovascular disease. The gene discussed is SERPINE1; the disease is cardiovascular disorder.